DNA cross-linking by bromo-isophosphoramide mustard (released under hypoxic conditions)

Bromo-isophosphoramide mustard–induced DNA cross-linking is the primary cytotoxic mechanism underlying certain hypoxia-targeted chemotherapeutics such as evofosfamide (TH‑302). These agents are designed as prodrugs that remain inert under normal oxygen levels but become activated by cellular reductases within severely hypoxic regions common in solid tumors. Upon activation, they release bromo-isophosphoramide mustard—a bifunctional alkylator—which forms covalent interstrand and intrastrand links between guanine bases on opposite strands of genomic DNA. This prevents proper unwinding during replication/transcription processes and triggers irreparable damage responses including histone H2AX phosphorylation. The result is robust induction of cell cycle arrest followed by apoptotic death preferentially within poorly vascularized tumor zones while sparing normoxic healthy tissues. Sensitivity is heightened in cells lacking efficient homologous recombination repair mechanisms such as those with BRCA mutations.

Other names

Br-IPM-induced DNA cross-linksHypoxia-activated alkylating agent–mediated DNA damageEvofosfamide/TH-302 mechanism of action

Under hypoxic conditions within tumors, evofosfamide is enzymatically reduced and fragments to release bromo-isophosphoramide mustard. Br-IPM acts as an alkylating agent that forms both intrastrand and interstrand covalent bonds between guanine bases on opposing strands ("cross-links") in cellular DNA. These lesions block replication and transcription machinery, leading to S139 phosphorylation on histone H2AX (a marker for double-strand breaks), cell cycle arrest at G2/M phase, and ultimately apoptosis if unrepaired. Cells deficient in homologous recombination repair pathways are especially sensitive.